Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538426 | 0.91 | HSD17B10 (0.41) | TP53HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6538480 | 0.89 | HSD17B10 (0.44) | TP53MEN1KMT2APDE4BPDE4A | |
| SCHEMBL6538489 | 0.89 | MEN1 (0.49) | TP53HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6539234 | 0.88 | HSD17B10 (0.44) | TP53MEN1KMT2APDE4BPDE4A | |
| SCHEMBL6539249 | 0.88 | TP53 (0.40) | TP53HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6539046 | 0.88 | TP53 (0.45) | TP53HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6538899 | 0.86 | TP53 (0.43) | TP53HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6538310 | 0.85 | BRD4 (0.42) | TP53HTTMEN1KMT2AMAPT | |
| SCHEMBL6539022 | 0.84 | TP53 (0.42) | TP53HTTMEN1KMT2AMAPT | |
| SCHEMBL6538395 | 0.83 | TP53 (0.52) | TP53HTTSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067955-A1 | Pyridazinone compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067955-A1 | Pyridazinone compound and pharmaceutical use thereof | ADORA1, ADORA2A, P2RX5 | TP53 3830/4885HTT 478/4885MEN1 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.